Alpa Laboratories Limited (ALPA)

Loading page…

Alpa Laboratories Limited (ALPA) · mywealthgrid

About

Alpa Laboratories Limited is a pharmaceuticals company in India's healthcare sector. With a market capitalization of ₹133.81 Cr and recent quarterly revenues ranging from ₹23.93 Cr to ₹31.4 Cr, it operates as a mid-sized pharma player. The company has generated profits in most recent quarters, though with significant volatility.

Face value: ₹10

Market cap

₹124 Cr

P/E

28.5×

P/B

0.7×

Dividend yield

ROE

8.4%

ROCE

9.3%

Debt / equity

0.01

OPM

3.1%

EPS (TTM)

₹2.1

Book value

₹88.5

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Severe operating margin volatility: OPM swung from -16.55% in Jun 2026 to 11.5% in Mar 2026, indicating inconsistent execution — verify drivers of margin compression and sustainability of profitability
Thin overall margins: 3.11% OPM masks quarterly deterioration, constraining financial cushion and investor confidence
High valuation relative to returns: PE of 30.62 appears stretched given 8.39% ROE and inconsistent quarterly earnings
Unexplained stock decline: Down 33.8% over one year despite minimal debt (D/E 0.01) — verify operational or competitive pressures underlying underperformance

Generated analysis · source review pending

Growth drivers

Historical operating margins reached 11.5% (Mar 2026) and 7.21% (Dec 2025) before declining to -16.55% (Jun 2026), suggesting operational leverage exists if execution stabilizes
Minimal leverage (D/E 0.01) provides balance sheet capacity for growth investments or market expansion
Quarterly revenues of ₹25.63–₹31.4 Cr establish a base; growth from here requires verification of market positioning, product pipeline, and competitive standing

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹59.3-0.8%1Y

Quick read

rule-based

Pros

+Profit CAGR of 15.7% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 65.2×

Cons

−Low return on equity of 10.7% (3-yr avg)
−Thin operating margin of 3.1%
−Modest revenue growth of 1.6% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

51/100

Business quality: 45
Growth: 35
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	86	98	112	92	109	112	106
COGS	51	59	70	57	68	70	66
Gross profit	35	38	43	35	41	42	39
	32	30	32	28	33	38	36
	3	8	11	8	8	5	3
OPM %	3.9%	7.9%	9.5%	8.2%	7.5%	4.2%	3.1%
Depreciation	3	1	2	1	2	2	2
Interest	0	0	0	0	0	0	0
	3	4	11	10	15	23	16
Profit before tax	3	11	20	16	21	26	17
Tax	1	4	5	3	4	6	2
Tax %	36.1%	32.8%	28%	20.8%	18.9%	24%	10.1%
	2	7	14	13	17	20	15
PAT margin %	2.2%	7.4%	12.6%	13.7%	15.4%	17.3%	14.2%
EPS (₹)	0.9	3.5	6.7	5.9	8	9.3	6.7
EPS adjusted (₹)	—	3.4	6.7	6	8	9.3	7.1
Annual report	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	21	21	21	21	21	21
Reserves	87	101	114	131	150	165
	0	6	2	5	0	3
	33	28	31	25	51	53
Total equity & liabilities	140	155	167	183	223	242
	7	9	7	11	21	20
CWIP	2	0	0	0	0	0
Investments	51	75	78	98	118	142
	81	71	82	73	84	80
Total assets	140	155	167	183	223	242

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	40.7%	39%	37.9%	38.2%	37.4%

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.19%	57.19%
	0.11%	0.95%	0.5%	0.36%	0.74%	0.35%	0.4%	0.36%	0.35%	0.36%	0.38%	0.35%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.07%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	42.6%	41.76%	42.21%	42.35%	41.97%	42.36%	42.31%	42.35%	42.36%	42.35%	42.43%	42.39%
No. of shareholders	—	—	—	—	—	—	—	—	18,542	18,236	17,900	17,643

Promoter holding down 0.1 percentage points since Sep 2023.

71 deals · 6 Dec 2021 – 30 Sept 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Sept 2024	AAKRAYA RESEARCH LLP	Bulk	NSE	Sell	2,46,714	₹140.23	₹3.46 Cr
30 Sept 2024	AAKRAYA RESEARCH LLP	Bulk	NSE	Buy	2,46,714	₹140.07	₹3.46 Cr
30 Sept 2024	QE SECURITIES LLP	Bulk	NSE	Buy	2,03,805	₹139.76	₹2.85 Cr
30 Sept 2024	QE SECURITIES LLP	Bulk	NSE	Sell	2,00,761	₹139.75	₹2.81 Cr
30 Sept 2024	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	1,83,809	₹138.69	₹2.55 Cr
30 Sept 2024	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	1,83,809	₹138.79	₹2.55 Cr
30 Sept 2024	MUDUPULAVEMULA SURENDRANADHA REDDY	Bulk	NSE	Sell	1,69,278	₹139.35	₹2.36 Cr
30 Sept 2024	MUDUPULAVEMULA SURENDRANADHA REDDY	Bulk	NSE	Buy	1,69,278	₹139.21	₹2.36 Cr
30 Sept 2024	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	1,55,746	₹139.42	₹2.17 Cr
30 Sept 2024	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	1,38,942	₹139.81	₹1.94 Cr

1–10 of 71

1 / 8

Mr. MAHENDRA SINGH CHAWLAExecutive Director-Chairperson
Bakulesh C ShahChief Financial Officer
Mr. PARESH CHAWLAExecutive Director-MD
Mr. PRAVIN CHANDRA SHAHExecutive Director
Mr. VITTHAL KOTHANAExecutive Director
Mr. SHITUL SHAHExecutive Director
Mrs. PRATIBHA LUNAWATNon-Executive - Independent Director
Mr. SANKET BAHETINon-Executive - Independent Director
Mr. SUNIL KUMAR VALECHANon-Executive - Independent Director
Mr. PRATIK SHAHNon-Executive - Independent Director

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Alpa Laboratories Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

11 announcementsExport CSV

30 Sept 2026, 9:58 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

29 Sept 2026, 12:38 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

17 Sept 2026, 6:07 pmCompany Update

Appointment of Company Secretary and Compliance Officer

Appointment of Company Secretary / Compliance Officer PDF

7 Sept 2026, 9:40 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

7 Sept 2026, 3:45 pmCorp. Action

Fixes Book Closure For The Purpose Of AGM.

Book Closure PDF

7 Sept 2026, 2:13 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

13 Aug 2026, 8:29 pmResult

Results For The Quarter Ended June 2026

Financial Results PDF

11 Aug 2026, 5:57 pmCompany Update

CLARIFICATION ON BOARD MEETING

General PDF

Date	Category	Subject	Filing
30 Sept 2026, 9:58 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
29 Sept 2026, 12:38 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	40.7%	39%	37.9%	38.2%	37.4%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-2	2	-5	4	7	10
	6	-16	1	-13	-1	-12
	-0	6	-3	3	-5	2
Net cash flow	4	-8	-7	-7	0	1
Free cash flow	-5	-0	-6	-3	-4	6
CFO / Operating profit %	-19.6%	18.5%	-64.2%	45.1%	148.6%	302.4%

Leverage
Current ratio	—	3.7	4.42	4.98	5.69	4.1	4.01

Return ratios
Return on assets %	—	5.2%	9.1%	7.5%	9.2%	8.8%	6.2%

Alpa Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Working capital
Receivable days	—	133	124	185	139	152	141

Alpa Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Not in the F&O segment

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Ratio timeline

Board meetings1

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1